相关实验视频
Updated: Mar 14, 2026

12:24
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
Published on: June 3, 2014
12.8K
通过蛋白S和TFPIα-fVshort-protein S复合体抑制血栓的机制
Alexander G Ginsberg1, Josefin Ahnström2, James T B Crawley2
1Department of Mathematics, University of Utah, Salt Lake City, UT, USA.
Biophysical journal
|March 13, 2026
概括
蛋白S复合体 (PSC) 通过增强组织因子通路抑制剂α (TFPIα) 来强烈抑制血栓的产生. 数学建模显示,PSC在血小板上的积累会影响出血障碍和血友病A.
科学领域:
- 生物化学 生物化学
- 血液学 血液学 血液学
- 计算生物学 计算生物学
背景情况:
- 蛋白S (PS) 是一种关键的抗凝剂,与出血和血栓性疾病有关.
- PS增强了组织因子通路抑制剂α (TFPIα) 的抗凝活动.
- 建议三分子复合体TFPIα-PS-fV-简称蛋白质S复合体 (PSC) 调节血栓的产生.
研究的目的:
- 研究PSC的抗凝机制及其在血液凝固中的作用.
- 阐明PS如何在PSC中与TFPIα一起运作.
- 模拟PSC对血栓生成和出血障碍的影响.
主要方法:
- 一个经过实验验证的血液凝固数学模型的扩展.
- 在血中包含自由PS和PSC,在血小板上包含自由PS和TFPIα.
- 在各种条件下模拟凝血动态,包括流量和特定的出血障碍.
主要成果:
- 在凝血开始后不久,PSC显著抑制了血栓的产生.
- PSC与抑制Xa因子 (fXa) 的结合亲和力极大地调节了其抗凝效应.
- 在流量条件下 (~50倍的血度),PSC会在血小板上积累,并占据fV特定的结合点.
- 升高的PSC水平加剧了东德克萨斯州出血障碍中的出血;降低PSC改善了fV缺乏症中的血栓生成.
结论:
- PSC度和功能的变化极大地影响出血障碍的严重程度.
- 阻止PSC的抗凝功能可能为严重的血友病A提供治疗益处.
- 这项研究为PSC在血液静止和血栓形成中的复杂作用提供了新的见解.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Clot Retraction and Fibrinolysis
9.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.9K
Extrinsic and Intrinsic Pathways of Hemostasis
14.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
14.6K
Venous Thrombosis III: Interprofessional Care
449
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
449
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Coagulation
11.6K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
11.6K

